Quest PharmaTech Inc.
QPTFF
$0.01
$0.00-11.33%
OTC PK
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -23.08% | 14.21% | -47.52% | 47.67% | -56.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.11% | -3.06% | -25.32% | 55.85% | -71.26% |
| Operating Income | 13.11% | 3.06% | 25.32% | -55.85% | 71.26% |
| Income Before Tax | -124.40% | 177.03% | 18.67% | 104.54% | 507.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -124.40% | 177.03% | 18.67% | 104.54% | 507.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -124.40% | 177.03% | 18.67% | 104.54% | 507.05% |
| EBIT | 13.11% | 3.06% | 25.32% | -55.85% | 71.26% |
| EBITDA | -- | -- | 25.51% | -55.33% | 71.25% |
| EPS Basic | -125.81% | 176.32% | 19.54% | 106.06% | 487.50% |
| Normalized Basic EPS | -155.56% | 100.00% | 11.11% | 66.67% | 280.00% |
| EPS Diluted | -125.81% | 176.32% | 19.54% | 106.06% | 487.50% |
| Normalized Diluted EPS | -155.56% | 100.00% | 11.11% | 66.67% | 280.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |